SWOG clinical trial number
S0220

A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)

Closed
Phase
Accrual
92%
Published
Abbreviated Title
Cis/VP-16/RT/Surgery/Doc/Selected IIB, Stage IIIA or IIIB (Pancoast Tumors)
Activated
07/01/2003
Closed
10/01/2007
Participants
NCORP, Members, Medical Oncologists, ECOG, NCCTG, ACOSOG, CALGB, NCIC-CTG

Research committees

Lung Cancer

Treatment

Cisplatin Docetaxel VP-16 Radiation Therapy Surgery RT

Eligibility Criteria Expand/Collapse

Pts must have histologic/cytologically-confirmed newly diagnosed, single primary bronchogenic NSCLC, selected Stage IIB, Stage IIIA or IIIB due to involvement of superior sulcus (T3-4, N0-1); EKG obtained; evidence of disease by chest X-ray (PA and lateral views), chest CT (preferable w/contrast) w/bone windows, CT scan of upper abdomen or PET scan (not necessary if chest CT incl. liver and adrenals) and biopsy or aspiration of any suspicious CT/MRI findings; Pleural effusion negative per Section 5.18; Pre-resection FEV1 >/= 2.0 L or if FEV1 < 2.0, predicted post-resection FEV1 > 1.0 L; Zubrod PS 0-2 (PS 2 must have albumin >/= 0.85 x ILLN, Weight Loss </= 10%); ANC >/= 1,500 and PLTS >/= 100,000; adequate hepatic function, total bili and SGOT or SGPT </= 1.5 x IULN (unless benign disese present); CrCl >/= 50 ml/min; Pts must have mediastinal exploration w/lymph nodes biopsied except if mediastinum is negative by both PET and CT; Attending surgeon, medical oncologist and radiation oncologist must approve the staging designation prior to registration; Pts must not have had prior malignancy except: treated basal cell or squamous cell skin ca, in situ cervical ca and must be disease-free for 5 yrs; Pts must be a candidate for future pulmonary resection; Pts must not have mediastinal or supraclavicular nodal involvement (N2-3); Pts must not have 2 or more parenchymal lesions in the same or both lungs; Pts must not have malignant pericardial effusions or SVC syndrome; Pts must not have had prior chemo or radiation to the thorax, head or neck region (thoracotomy for staging purposes only); Pts must not have evidence of distant mets via bone scan or PET scan; Pts must not have unstable cardiac rhythms, uncontrolled CHF, PUD, active angina or recent MI; Pt must not have brain mets via CT or MRI of the brain; Pts must not have > Grade 1 neuropathy-sensory; Pts must not be pregnant or nursing or of reproductive potential and not agreed to use effective contraceptive method; Pts must be offered participation in S9925 (the Lung Cancer Specimen Repository); Pts must not have hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.

Publication Information Expand/Collapse

2014

Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup trial S0220

K Kernstine;J Moon;M Kraut;K Pisters;J Sonett;V Rusch;C Thomas;T Waddell;J Jett;A Lyss;S Keller;D Gandara Annals of Thoracic Surgery 98(2):402-410;

PMid: PMID24980603 | PMC number: PMC4122593

2013

Induction chemoradiotherapy followed by consolidation cytotoxic therapy for superior sulcus (Pancoast tumors) non-small cell lung cancer: a SWOG-coordinated feasibility phase II intergroup trial (S0220)

K Kernstine;J Moon;M Kraut;K Pisters;J Sonett;V Rusch;CR Thomas;T Waddell;J Jett;A Lyss;S Keller;D Gandara Annals of Thoracic Surgery 94(6):2172-2175; Society of Thoracic Surgeons 2013 Annual Meeting (Jan 26-30, 2013, Los Angeles, CA), oral presenation;

2009

Docetaxel is not feasible as consolidation therapy after cisplatin/etoposide/concurrent radiotherapy followed by surgical resection for pancoast tumors: preliminary results of SWOG 0220

MJ Kraut;J Moon;CR Thomas;J Sonett;J Jett;V Rusch;AP Lyss;H Gillenwater;S Laurie;D Gandara Journal of Thoracic Oncology 4(9)suppl 1, abst. PD8.2.6,S522, 2009 (IASLC 13th World Conf on Lung Cancer, poster)

2008

Cooperative group research efforts in lung cancer: focus on early stage non-small cell lung cancer

H Wakelee;C Langer;E Vokes;J Schiller;P Bass;N Saijo;A Adjei;F Shepherd;H Choy;DR Gandara Clinical Lung Cancer 9(1):9-15

PMid: PMID18282352 | PMC number: (Reviews are not within the scope of the Public Access )

2005

Therapeutic strategies for combined-modality therapy of locally advanced non-small cell lung cancer: rationale for consolidation docetaxel therapy

DR Gandara;E Vallieres;LE Gaspar;K Kelly;KS Albain;RS Herbst Jr;PN Lara Jr;P Mack;PH Gumerlock;JJ Crowley Clinical Lung Cancer 7 Suppl 3:S93-97

Other Clinical Trials

SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)

Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007